Loading…

Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection

To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children's Hospital Ljubljana, Slovenia, from J...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2024-03, Vol.26 (1), p.69-69, Article 69
Main Authors: Zajc Avramovič, Mojca, Toplak, Nataša, Markelj, Gašper, Emeršič, Nina, Avčin, Tadej
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c515t-5288f3deed335ed6c37f2f0a1edaa85d948b1a8efe60523e62e07047df5be8903
container_end_page 69
container_issue 1
container_start_page 69
container_title Arthritis research & therapy
container_volume 26
creator Zajc Avramovič, Mojca
Toplak, Nataša
Markelj, Gašper
Emeršič, Nina
Avčin, Tadej
description To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children's Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular corticosteroid injection (IAC) as the initial treatment. Patient and treatment data were collected, and the outcomes were categorized into three groups based on the later need for therapy: no therapy needed, only additional IAC needed and systemic therapy needed. The last group was further divided based on the requirement of bDMARD. Log-rank (Mantel-Cox) survival analyses compared different outcome groups. We included 109 patients with JIA, presenting as oligoarthritis (63% female), who were first treated with IAC. The mean age at IAC was 8.0 years, with a 4.3-year follow-up. Notably, 38.5% of patients did not require additional therapy post-IAC, whereas 15.5% required only additional IAC. Systemic therapy, mainly methotrexate (MTX), was necessary for 45.9% of patients, initiated in average 7.8 months post-IAC. Biologic therapy was initiated in 22% in average 2.2 years post-IAC. Number of injected joints correlated with the need for biologics. At the last follow-up, 88.9% had inactive disease. ANA positivity (P = 0.049, chi square 3.89) and HLA B27 antigen presence (P = 0.050, chi square 3.85) were associated with the need for systemic therapy. A subgroup of children older than 8 years, ANA and HLA B27 negative required significantly less systemic (25.8%) and biologic therapy (9.6%) compared to other patients (p = 0.050, chi square 3.77). Almost 40% of children with oligoarticular JIA requiring IAC did not progress to chronic disease. Younger age, ANA positivity, and HLA B27 presence were predictive factors for systemic therapy, while the number of injected joints predicted the future need for biologic therapy.
doi_str_mv 10.1186/s13075-024-03303-y
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e47b684b433c485d821349fe16cfcfda</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A786475353</galeid><doaj_id>oai_doaj_org_article_e47b684b433c485d821349fe16cfcfda</doaj_id><sourcerecordid>A786475353</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-5288f3deed335ed6c37f2f0a1edaa85d948b1a8efe60523e62e07047df5be8903</originalsourceid><addsrcrecordid>eNptkk1vEzEQhlcIREvhD3BAlrhw2eLv9Z5QVfFRKRIXOFuOPU4cOetg77bKrT8db1JKg5APtjzvPPbMvE3zluBLQpT8WAjDnWgx5S1mDLN2_6w5J7xTrWSSPn9yPmtelbLBmNKe8pfNGVNcSarEeXO_SMOqHSFvkU8xprt22qHkEcE9susQXYYB3YVxjTbTLQwhAgoupJ0Z18GiFMMqmTyucxhDQcZXEPIhlxGFYcymrbFgp2gysmk-plIVKbga3oAdQxpeNy-8iQXePOwXzc8vn39cf2sX37_eXF8tWiuIGFtBlfLMATjGBDhpWeepx4aAM0YJ13O1JEaBB4kFZSAp4A7zznmxBNVjdtHcHLkumY3e5bA1ea-TCfpwkfJKHz4bQQPvllLxJWfM8spWlDDeeyDSeuudqaxPR9ZuWm7BWZhrjSfQ08gQ1nqVbnXtKlOKyEr48EDI6dcEZdTbUCzEaAZIU9G0F4rWmoSo0vf_SDdpykPt1aySM06wv6qVqRWEwaf6sJ2h-qpTkneCHVSX_1HV5WBbhzOArwM-TaDHBJtTKRn8Y5EE69mE-mhCXU2oDybU-5r07ml7HlP-uI79Bie_2kA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956881653</pqid></control><display><type>article</type><title>Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Zajc Avramovič, Mojca ; Toplak, Nataša ; Markelj, Gašper ; Emeršič, Nina ; Avčin, Tadej</creator><creatorcontrib>Zajc Avramovič, Mojca ; Toplak, Nataša ; Markelj, Gašper ; Emeršič, Nina ; Avčin, Tadej</creatorcontrib><description>To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children's Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular corticosteroid injection (IAC) as the initial treatment. Patient and treatment data were collected, and the outcomes were categorized into three groups based on the later need for therapy: no therapy needed, only additional IAC needed and systemic therapy needed. The last group was further divided based on the requirement of bDMARD. Log-rank (Mantel-Cox) survival analyses compared different outcome groups. We included 109 patients with JIA, presenting as oligoarthritis (63% female), who were first treated with IAC. The mean age at IAC was 8.0 years, with a 4.3-year follow-up. Notably, 38.5% of patients did not require additional therapy post-IAC, whereas 15.5% required only additional IAC. Systemic therapy, mainly methotrexate (MTX), was necessary for 45.9% of patients, initiated in average 7.8 months post-IAC. Biologic therapy was initiated in 22% in average 2.2 years post-IAC. Number of injected joints correlated with the need for biologics. At the last follow-up, 88.9% had inactive disease. ANA positivity (P = 0.049, chi square 3.89) and HLA B27 antigen presence (P = 0.050, chi square 3.85) were associated with the need for systemic therapy. A subgroup of children older than 8 years, ANA and HLA B27 negative required significantly less systemic (25.8%) and biologic therapy (9.6%) compared to other patients (p = 0.050, chi square 3.77). Almost 40% of children with oligoarticular JIA requiring IAC did not progress to chronic disease. Younger age, ANA positivity, and HLA B27 presence were predictive factors for systemic therapy, while the number of injected joints predicted the future need for biologic therapy.</description><identifier>ISSN: 1478-6362</identifier><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>DOI: 10.1186/s13075-024-03303-y</identifier><identifier>PMID: 38486285</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>ANA ; Children ; Chronic illnesses ; Corticosteroids ; Disease ; Dosage and administration ; Drug therapy ; Drugs ; Health aspects ; Juvenile arthritis ; Juvenile idiopathic arthitis ; Long-term follow-up ; Medical prognosis ; Methotrexate ; Missing data ; Oligoarthritis ; Outcome ; Patient outcomes ; Patients ; Pediatric arthritis ; Pediatrics ; Psoriatic arthritis ; Remission (Medicine) ; Rheumatology ; Risk factors</subject><ispartof>Arthritis research &amp; therapy, 2024-03, Vol.26 (1), p.69-69, Article 69</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c515t-5288f3deed335ed6c37f2f0a1edaa85d948b1a8efe60523e62e07047df5be8903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10938816/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2956881653?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38486285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zajc Avramovič, Mojca</creatorcontrib><creatorcontrib>Toplak, Nataša</creatorcontrib><creatorcontrib>Markelj, Gašper</creatorcontrib><creatorcontrib>Emeršič, Nina</creatorcontrib><creatorcontrib>Avčin, Tadej</creatorcontrib><title>Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection</title><title>Arthritis research &amp; therapy</title><addtitle>Arthritis Res Ther</addtitle><description>To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children's Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular corticosteroid injection (IAC) as the initial treatment. Patient and treatment data were collected, and the outcomes were categorized into three groups based on the later need for therapy: no therapy needed, only additional IAC needed and systemic therapy needed. The last group was further divided based on the requirement of bDMARD. Log-rank (Mantel-Cox) survival analyses compared different outcome groups. We included 109 patients with JIA, presenting as oligoarthritis (63% female), who were first treated with IAC. The mean age at IAC was 8.0 years, with a 4.3-year follow-up. Notably, 38.5% of patients did not require additional therapy post-IAC, whereas 15.5% required only additional IAC. Systemic therapy, mainly methotrexate (MTX), was necessary for 45.9% of patients, initiated in average 7.8 months post-IAC. Biologic therapy was initiated in 22% in average 2.2 years post-IAC. Number of injected joints correlated with the need for biologics. At the last follow-up, 88.9% had inactive disease. ANA positivity (P = 0.049, chi square 3.89) and HLA B27 antigen presence (P = 0.050, chi square 3.85) were associated with the need for systemic therapy. A subgroup of children older than 8 years, ANA and HLA B27 negative required significantly less systemic (25.8%) and biologic therapy (9.6%) compared to other patients (p = 0.050, chi square 3.77). Almost 40% of children with oligoarticular JIA requiring IAC did not progress to chronic disease. Younger age, ANA positivity, and HLA B27 presence were predictive factors for systemic therapy, while the number of injected joints predicted the future need for biologic therapy.</description><subject>ANA</subject><subject>Children</subject><subject>Chronic illnesses</subject><subject>Corticosteroids</subject><subject>Disease</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Health aspects</subject><subject>Juvenile arthritis</subject><subject>Juvenile idiopathic arthitis</subject><subject>Long-term follow-up</subject><subject>Medical prognosis</subject><subject>Methotrexate</subject><subject>Missing data</subject><subject>Oligoarthritis</subject><subject>Outcome</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Pediatric arthritis</subject><subject>Pediatrics</subject><subject>Psoriatic arthritis</subject><subject>Remission (Medicine)</subject><subject>Rheumatology</subject><subject>Risk factors</subject><issn>1478-6362</issn><issn>1478-6354</issn><issn>1478-6362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1vEzEQhlcIREvhD3BAlrhw2eLv9Z5QVfFRKRIXOFuOPU4cOetg77bKrT8db1JKg5APtjzvPPbMvE3zluBLQpT8WAjDnWgx5S1mDLN2_6w5J7xTrWSSPn9yPmtelbLBmNKe8pfNGVNcSarEeXO_SMOqHSFvkU8xprt22qHkEcE9susQXYYB3YVxjTbTLQwhAgoupJ0Z18GiFMMqmTyucxhDQcZXEPIhlxGFYcymrbFgp2gysmk-plIVKbga3oAdQxpeNy-8iQXePOwXzc8vn39cf2sX37_eXF8tWiuIGFtBlfLMATjGBDhpWeepx4aAM0YJ13O1JEaBB4kFZSAp4A7zznmxBNVjdtHcHLkumY3e5bA1ea-TCfpwkfJKHz4bQQPvllLxJWfM8spWlDDeeyDSeuudqaxPR9ZuWm7BWZhrjSfQ08gQ1nqVbnXtKlOKyEr48EDI6dcEZdTbUCzEaAZIU9G0F4rWmoSo0vf_SDdpykPt1aySM06wv6qVqRWEwaf6sJ2h-qpTkneCHVSX_1HV5WBbhzOArwM-TaDHBJtTKRn8Y5EE69mE-mhCXU2oDybU-5r07ml7HlP-uI79Bie_2kA</recordid><startdate>20240314</startdate><enddate>20240314</enddate><creator>Zajc Avramovič, Mojca</creator><creator>Toplak, Nataša</creator><creator>Markelj, Gašper</creator><creator>Emeršič, Nina</creator><creator>Avčin, Tadej</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240314</creationdate><title>Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection</title><author>Zajc Avramovič, Mojca ; Toplak, Nataša ; Markelj, Gašper ; Emeršič, Nina ; Avčin, Tadej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-5288f3deed335ed6c37f2f0a1edaa85d948b1a8efe60523e62e07047df5be8903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>ANA</topic><topic>Children</topic><topic>Chronic illnesses</topic><topic>Corticosteroids</topic><topic>Disease</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Health aspects</topic><topic>Juvenile arthritis</topic><topic>Juvenile idiopathic arthitis</topic><topic>Long-term follow-up</topic><topic>Medical prognosis</topic><topic>Methotrexate</topic><topic>Missing data</topic><topic>Oligoarthritis</topic><topic>Outcome</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Pediatric arthritis</topic><topic>Pediatrics</topic><topic>Psoriatic arthritis</topic><topic>Remission (Medicine)</topic><topic>Rheumatology</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zajc Avramovič, Mojca</creatorcontrib><creatorcontrib>Toplak, Nataša</creatorcontrib><creatorcontrib>Markelj, Gašper</creatorcontrib><creatorcontrib>Emeršič, Nina</creatorcontrib><creatorcontrib>Avčin, Tadej</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Arthritis research &amp; therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zajc Avramovič, Mojca</au><au>Toplak, Nataša</au><au>Markelj, Gašper</au><au>Emeršič, Nina</au><au>Avčin, Tadej</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection</atitle><jtitle>Arthritis research &amp; therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2024-03-14</date><risdate>2024</risdate><volume>26</volume><issue>1</issue><spage>69</spage><epage>69</epage><pages>69-69</pages><artnum>69</artnum><issn>1478-6362</issn><issn>1478-6354</issn><eissn>1478-6362</eissn><abstract>To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children's Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular corticosteroid injection (IAC) as the initial treatment. Patient and treatment data were collected, and the outcomes were categorized into three groups based on the later need for therapy: no therapy needed, only additional IAC needed and systemic therapy needed. The last group was further divided based on the requirement of bDMARD. Log-rank (Mantel-Cox) survival analyses compared different outcome groups. We included 109 patients with JIA, presenting as oligoarthritis (63% female), who were first treated with IAC. The mean age at IAC was 8.0 years, with a 4.3-year follow-up. Notably, 38.5% of patients did not require additional therapy post-IAC, whereas 15.5% required only additional IAC. Systemic therapy, mainly methotrexate (MTX), was necessary for 45.9% of patients, initiated in average 7.8 months post-IAC. Biologic therapy was initiated in 22% in average 2.2 years post-IAC. Number of injected joints correlated with the need for biologics. At the last follow-up, 88.9% had inactive disease. ANA positivity (P = 0.049, chi square 3.89) and HLA B27 antigen presence (P = 0.050, chi square 3.85) were associated with the need for systemic therapy. A subgroup of children older than 8 years, ANA and HLA B27 negative required significantly less systemic (25.8%) and biologic therapy (9.6%) compared to other patients (p = 0.050, chi square 3.77). Almost 40% of children with oligoarticular JIA requiring IAC did not progress to chronic disease. Younger age, ANA positivity, and HLA B27 presence were predictive factors for systemic therapy, while the number of injected joints predicted the future need for biologic therapy.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38486285</pmid><doi>10.1186/s13075-024-03303-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1478-6362
ispartof Arthritis research & therapy, 2024-03, Vol.26 (1), p.69-69, Article 69
issn 1478-6362
1478-6354
1478-6362
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e47b684b433c485d821349fe16cfcfda
source Publicly Available Content Database; PubMed Central
subjects ANA
Children
Chronic illnesses
Corticosteroids
Disease
Dosage and administration
Drug therapy
Drugs
Health aspects
Juvenile arthritis
Juvenile idiopathic arthitis
Long-term follow-up
Medical prognosis
Methotrexate
Missing data
Oligoarthritis
Outcome
Patient outcomes
Patients
Pediatric arthritis
Pediatrics
Psoriatic arthritis
Remission (Medicine)
Rheumatology
Risk factors
title Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A47%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20follow-up%20of%20109%20children%20with%20juvenile%20idiopathic%20oligoarthritis%20after%20first%20intra-articular%20corticosteroid%20injection&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Zajc%20Avramovi%C4%8D,%20Mojca&rft.date=2024-03-14&rft.volume=26&rft.issue=1&rft.spage=69&rft.epage=69&rft.pages=69-69&rft.artnum=69&rft.issn=1478-6362&rft.eissn=1478-6362&rft_id=info:doi/10.1186/s13075-024-03303-y&rft_dat=%3Cgale_doaj_%3EA786475353%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c515t-5288f3deed335ed6c37f2f0a1edaa85d948b1a8efe60523e62e07047df5be8903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956881653&rft_id=info:pmid/38486285&rft_galeid=A786475353&rfr_iscdi=true